National Bank of Canada
KNSA icon

National Bank of Canada’s Kiniksa Pharmaceuticals KNSA Stock Holding History

National Bank of Canada’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-494
Closed -$9.77K – 3006
2024
Q4 		$9.77K Sell
494
-7
-1% -$160 ﹤0.01% 2335
2024
Q3 		$12.5K Buy
501
+1
+0.2% +$24 ﹤0.01% 2034
2024
Q2 		$8.96K Hold
500
– – ﹤0.01% 2146
2024
Q1 		$9.76K Buy
+500
New +$9.77K ﹤0.01% 2181
2022
Q3 		– Sell
-500
Closed -$5K – 2796
2022
Q2 		$5K Hold
500
– – ﹤0.01% 2429
2022
Q1 		$5K Buy
+500
New +$5.3K ﹤0.01% 2550

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada's KNSA Position: Q1 2025 in Review

National Bank of Canada sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 494 shares — an estimated $9.77K sold.

National Bank of Canada first reported a position in KNSA in Q1 2022 and held it in 6 quarters. The position peaked at $12.5K in Q3 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • National Bank of Canada reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 494 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $9.77K.
  • National Bank of Canada first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • National Bank of Canada's Kiniksa Pharmaceuticals position peaked at $12.5K in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.